Outcomes According to ALKStatus Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
- Resource Type
- Article
- Authors
- Mok, Tony; Peters, Solange; Camidge, D. Ross; Noé, Johannes; Gadgeel, Shirish; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Konopa, Krzysztof; Pozzi, Emanuela; Liu, Ting; Loftin, Isabell R.; Williams, Crystal; Shaw, Alice T.
- Source
- Journal of Thoracic Oncology; February 2021, Vol. 16 Issue: 2 p259-268, 10p
- Subject
- Language
- ISSN
- 15560864; 15561380
We retrospectively examined progression-free survival (PFS) and response by ALKfluorescence in situ hybridization (FISH) status in patients with advanced ALKimmunohistochemistry (IHC)-positive NSCLC in the ALEX study.